Novartis AG (NVSN) — Cash Flow Reinvestment Rate
Novartis AG (NVSN) has a Cash Flow Reinvestment Rate of 0.52x as of March 2026, reinvesting MX$1.92 Billion (capex MX$807.00 Million plus investments MX$1.11 Billion) from operating cash flow of MX$3.68 Billion. See Novartis AG (NVSN) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Novartis AG Cash Flow Reinvestment Rate (2014–2025)
Historical reinvestment intensity for Novartis AG across 12 annual periods. For the full cash flow conversion analysis, see how efficiently does Novartis AG generate cash.
Annual Cash Flow Reinvestment Rate for Novartis AG (2014–2025)
Year-by-year capital reinvestment analysis for Novartis AG. See NVSN financial flexibility score to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (MXN) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.30x | MX$5.77 Billion | MX$19.14 Billion | MX$3.90 Billion | ▲ +37.4% |
| 2024 | 0.22x | MX$3.87 Billion | MX$17.62 Billion | MX$3.81 Billion | ▼ -60.0% |
| 2023 | 0.55x | MX$8.79 Billion | MX$16.02 Billion | MX$2.90 Billion | ▲ +33.5% |
| 2022 | 0.41x | MX$5.85 Billion | MX$14.24 Billion | MX$1.20 Billion | ▼ -24.4% |
| 2021 | 0.54x | MX$8.19 Billion | MX$15.07 Billion | MX$1.38 Billion | ▲ +237.8% |
| 2020 | 0.16x | MX$2.20 Billion | MX$13.65 Billion | MX$1.27 Billion | ▼ -51.9% |
| 2019 | 0.33x | MX$4.56 Billion | MX$13.62 Billion | MX$1.38 Billion | ▼ -60.6% |
| 2018 | 0.85x | MX$12.10 Billion | MX$14.27 Billion | MX$1.25 Billion | ▲ +690.9% |
| 2017 | 0.11x | MX$1.35 Billion | MX$12.62 Billion | MX$1.32 Billion | ▼ -80.5% |
| 2016 | 0.55x | MX$6.32 Billion | MX$11.47 Billion | MX$2.88 Billion | ▲ +134.2% |
| 2015 | 0.24x | MX$2.80 Billion | MX$11.90 Billion | MX$2.37 Billion | ▼ -46.4% |
| 2014 | 0.44x | MX$6.10 Billion | MX$13.90 Billion | MX$2.62 Billion | — |